We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

125 hedge funds and large institutions have $1.02B invested in Aimmune Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 29

45% more capital inflows, than outflows

Capital inflows: $88.5M | Capital outflows: $60.8M

38% more call options, than puts

Call options by funds: $5.91M | Put options by funds: $4.29M

1.71% more ownership

Funds ownership: 77.04% → 78.75% (+1.7%)

10% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 21

0% more funds holding

Funds holding: 125 → 125 (0)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
125
Holders Change
–
Holders Change %
0%
% of All Funds
2.7%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
23
Increased
49
Reduced
29
Closed
21
Calls
$5.91​M
Puts
$4.29​M
Net Calls
+$1.62​M
Net Calls Change
+$4.04​M

AIMT Hedge Fund Activity: Q2 2019 in Review

125 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2019, worth a combined $1.02B — down 4.3% from $1.07B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AIMT positions and 21 closed out — a net gain of 2 holders — while 49 added to existing stakes and 29 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $16.7M. The largest seller was Southpoint Capital Advisors, exiting entirely with an estimated $17.9M sold.

  • 125 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $1.02B of Aimmune Therapeutics stock for Q2 2019, down 4.3% quarter-over-quarter.
  • 23 funds opened new Aimmune Therapeutics positions in Q2 2019 and 21 closed out, a net change of +2 holders.
  • The largest Aimmune Therapeutics buyer in Q2 2019 was Eventide Asset Management, an estimated $16.7M added.
  • The largest Aimmune Therapeutics seller in Q2 2019 was Southpoint Capital Advisors, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2019.